In this study, we report pectin-Chitosan compression coated core tablets of Mesalamine for colonic delivery. Each 150 mg core tablet contained Mesalamine and was compression coated using 100% pectin 1:1, 10 pectin:1 Chitosan, or 10 pectin :2 Chitosan, at coat weights as 400mg. Drug dissolution or system erosion or degradation studies were carried out in pH 1.2, 6.8,7.4 phosphate buffers using a pectinolytic enzyme. The system was designed based on the gastrointestinal transit time concept, under the assumption of colon arrival times of 6 h. It was found that pectin alone was not sufficient to protect the core tablets and Chitosan addition was required to control the solubility of pectin. The optimum Chitosan concentration was 1 and such system would protect the cores up to 6 h and after that under the influence of pectinase the system would degrade faster and delivering 5-ASA to the colon. The pectin-Chitosan (10:1) envelope was found to be a promising drug delivery system for those drugs to be delivered to the colon.
INTRODUCTION
Delivery of a drug to a specific organ or tissue i.e. spatial placement and controlling the rate of drug delivery to the specific sites i.e. temporal delivery are the two main aspects of the drug delivery systems 1 . Now a day the colon has recently become accepted as an increasingly important site for drug delivery. Colon specific diseases are often inefficiently managed by oral therapy, colon specific drug delivery systems, which can deliver drugs to the lower gastrointestinal tract without releasing them in the upper GI-tract, can be expected to increase the quality of life for patients suffering from colon specific diseases. Treatment might be more effective if the drug substances were targeted directly on the site of action in the colon. The concentration of drug reaching the colon depends on formulation factors, the extent of retrograde spreading and the retention time 2 . Number of serious diseases of the colon might be capable of being treated more effectively if drugs were targeted on the colon. Therefore, it appears that targeted drug delivery with an appropriate release pattern could be crucial in providing effective therapy for these chronic diseases. In addition to providing more effective therapy of colon related diseases, colon specific delivery has the potential to address important unmet therapeutic needs including oral delivery of macromolecular drugs 3 . In the past two decades, the pharmaceutical scientists are extensively investigated in the area of colonic region for targeted drug delivery system Local action in the treatment of ulcerative colitis and Systemic absorption of protein and peptide drugs.
MATERIAL AND METHODS

Equipments used Method Micronization of Mesalamine Micronization Parameters (Spiral Air jet mill)
Air pressure -8 bar Grinding Pressure -4 kg/cm2 Ventury pressure -1 kg/cm2 Preparation of 5-ASA core tablets Weigh mesalamine, Sodium starch glycolate, MCC (Avicel PH 101) & pass through sieve no. 40. PVP (K 30) solution in water was prepared for granulation purpose. Wet granules were prepared & sieved through 18 no sieve and dried overnight at 40 0 C to obtain LOD up to 2% moisture content then granules pass through sieve no 20. After adding 4% magnesium stearate as a lubricant & talc as glidant lubricated granules compressed using a laboratory size multi station tablet press (Emtech) with 8 mm flat faced punches. Tablet quality control tests such as weight variation, crushing strength, friability, thickness, and dissolution were performed on the core tablets. [4] [5] [6] [7] Core tablets were first dedusted then placed in 12 mm die cavity of a laboratory multi press. Depending on the design 100%pectin, pectin: Chitosan (5:1), pectin: Chitosan (10:1) combinations were used for the outer shell compression the coat weights were 400 mg. Tablet quality control tests such as weight variation, crushin strength, friability, thickness, dissolution & erosion rates in different media were carried out.
Compression Coating of Core Tablets
Evaluation of Pre-compressed granules of Mesalamine Angle of repose
In this method weighed 20 gm of granule, allowed to flow DOI number: 10.25258/ijpcr.v9i1.8260 under gravity though funnel and angle of incline of the formed. That is produced is assayed by measuring the height and having a fixed base i.e. diameter.
Determination of Density Bulk Density
Determined by pouring granules in to a graduated, cylinder via large funnel in and measuring the volume and weighed. As tapped density is determined by placing a graduated cylinder containing a known mass of drug or formulation an a mechanical tapper apparatus. This is operated for a fixed no. of taps i.e. 100 taps. It is the ratio of tapped density to the bulk density. It is given by-Db=Tapped Density/Bulk Density Evaluation of the core tablets The tablets were subjected to evaluation for the following parameters.
Tablet Shape
It may be have a significant effect on the performance of applied functional films including enteric coatings. Shall oval shapes are more prone to edge attrition and may result in non uniform film coverage on the edges of the tablet.
Weight variation 20 tablets of each of formulation were weighed individually using an electronic balance. The average weight was calculated and individual tablet weight was compared with average value and the deviation was recorded.
Tablet hardness
Tablet hardness is also known as tablet crushing strength. Monsanto Hardness tester was used. It applies force to the tablet diametrically with the help of an in built spring. Triplicate determinations were done.
Friability test
Friability test is performed to assess the effect of abrasions and shock that may often cause tablet to chip, cap or break. Roche Friabilator was used for the purpose. Compressed tablets should not lose more than 1% of their weight (as per IP 96) It is a difficult job to maintain the percentage of friability within the limit, since all the methods of preparation of oral dispersible tablets have a tendency to increase the percentage of friability. In all aspect, the range is within limit of 0.1%-0.9%. Roche friabilator is used in conventional form in order to measure friability of the tablets 49 . Thickness The thickness of tablets was determined using Digital Vernier Caliper, (Mitutoyo, Japan). It is expressed in mm.
In vitro Disintegration time
The disintegration time of the tablet was measured in water (37±2°C) according to IP 96 disintegration test with disc. Three tablets from every batch (formulation) were tested for the disintegration time. The in-vitro disintegration time was determined using disintegration test apparatus. A tablet was placed in each of the six tubes of the apparatus and one disc was added to each tube. The time in seconds taken for complete disintegration of the tablet with no palatable mass remaining in the apparatus was measured in seconds 49, 60 .
Uniformity of content
The mesalamine content in tablets was determined by powdering 20 tablets in each batch. Powder equivalent to 100 mg of mesalamine was dissolved in 0.1 N HCl. 1 ml of filtrate was further diluted to 100 ml with 0.1 N HCl and it was determined by spectroscopy at 302 nm.
In vitro release profile of formulated Mesalamine tablet
All the tablet dissolution studies were carried out for three tablets (triplicate) per formulation. USP Type II dissolution apparatus was used for drug release studies. Following parameters were used in release study.
Characterization of Mesalamine compression coated tablets Hardness test
The prepared tablets were subjected to hardness test. It was carried out by using hardness tester and expressed in Kg/cm 2 .
Friability test
The friability was determined using Roche friabilator and expressed in percentage (%). 20 tablets from each batch were weighed separately (Winitial) and placed in the friabilator, which was then operated for 100 revolutions at 25 rpm. The tablets were reweighed (W final) and the percentage friability was calculated for each batch by using the following formula. F(%)=(Winitial -Wfinal) / Winitial *100 Weight variation test 20 tablets were selected at random from the lot, weighed individually and the average weight was determined. The percent deviation of each tablets weight against the average weight was calculated. The test requirements are met, if not more than two of the individual weights deviate from the average weight by more than 5% and none deviates more than 5%.
Test method for pectin-HPMC coat erosion
After compressing the tablets a erosion study was performed. First medium was 500 ml 0.1 N HCl solution. The USP XXIII dissolution apparatus 2 was used at 50 rpm at 37 0 C. The test was continued for 2 h, at the end of the time period the medium was discarded and refilled with USP pH 6.8 buffer solution and the test was continued for additional 6 h. After 6 h, depending on the design 1mg/ml Pectinase was added to the dissolution vessels containing 7.4 phosphate buffer and the test was continued until for a pre-determined time depending on the study design. Tablets were dried overnight at 45 0 C in an oven. In the case of drug dissolution 5-ASA concentration was determined spectrophotometrically at 303 nm (Shimadzu UV 1800, Japan). In vitro drug release studies Drug release studies were conducted under conditions mimicking mouth-to-colon transit. The dissolution medium consisted of 900 ml 0.1 mol/l HCl for 2 h, replaced by 900 ml phosphate buffer, pH 6.8 for 4 h, kept at 37 ± 0.5°C and stirred at 100 rpm, using USP dissolu-tion apparatus 2. Samples were withdrawn at the end of the specified periods (2 h and 4 h), filtered and assayed spectrophotometrically (UV-1800 UV-VIS-NIR, Shimadzu, Japan) for Mesalamine, at 301.5 nm in 0.1 mol/l HCl and 333.5nm in pH 6.8 buffer. After 6hr dissolution medium replaced with 7.4 phosphate buffer. To assess the susceptibility of the prepared Mesalamine delivery systems to the enzymatic action of colonic bacteria, drug release studies were continued in Phosphate buffer pH 7.4 in the absence (control) and presence of pectinase enzyme since these are known to have similar contents to those of human intestinal microflora. The studies were carried out using USP dissolution apparatus 2 (100 rpm, 37°C) Stability Study 8 FDA and ICH specifies, the guidelines for stability testing of new drug products, as a technical requirement for the registration of pharmaceuticals for human use. The ICH Tripartite Guidelines have established that long term stability testing should be done at 25°C/60% RH for 12 months. Accelerated stability testing should be done at 40°C/75% RH for 6 months. Stability testing at intermediate storage condition should done at 30°C/75% RH. In the present work, stability study was carried out for formulation containing pectin:chitosan(10:1), at 40°C ± 2 0 C, RH 75% ± 5% conditions for 2 months. Formulation Fp3 was selected for stability study because it protect drug release up to colon & gives faster drug release (100% within 9hrs) from the tablet and Fp3 have well dissolution time as compared to other formulations. The formulations were evaluated for hardness, friability, erosion study and In-Vitro drug release.
RESULT AND DISCUSSION
Preformulation Study of Mesalamine [9] [10] [11] Organoleptic Properties These test performed as per procedure given in method and material section. The results are illustrated in following shown below, Table 9 shows the results of Angle of Repose, Bulk Density, Tapped Density, Compressibility index, Hausner's ratio for various tablet formulations.
Evaluation of Precompressed granules of Mesalamine
Evaluation of formulations of Mesalamine core Tablets
The hardness values for core tablets of the all formulation were in the range between 3.0-4.0 Kg/cm2. The hardness of all tablets was kept within the above mentioned range to compare the disintegration time between the formulations prepared using different disintegrants and their varying concentrations. The friability of all formulations was determined. The friability values of none of the formulations exceeded 0.87%. The results of friability indicate that the tablets were mechanically stable and can withstand rigors of transportation and handling. Thickness of all tablets was between 2.6 -2.7 mm showing fairly uniform tableting. In vitro disintegration times for different tablets are given in the Table 6 . All formulations gave disintegration time between 40-50sec. As the concentration of the superdisintegrants has increased, the disintegration time of tablets increased. All 9 formulations passes the content uniformity, assay, average tablet weight is within the limit as per I.P. Specification. 
CONCLUSION
The present study has been satisfactorily attempted to formulate a colon targeted drug delivery of mesalamine using Pectin: chitosan (10:1) as coating material.From the experimental results it can be concluded that Fp3 batch is best batch. From all results formulations of core tablet f3 batch was selected as optimized batch. Production yield of fp3 was greater than other The production yield of Fp3 is 97.41%. The IR spectra revealed that there was no interaction between polymers and drug, hence they are compatible. From the DSC thermograms of pure mesalamine, mesalamine tablet of Fp3 batch, It was concluded that no interaction between the polymers and drug. The formulation Fp3 showed maximum drug content. Stability study of formulations (Fp3) with sodium starch glycolate showed that the properties of tablets were not altered significantly when kept at different conditions for two month. The optimum concentration of Pectin: chitosan is (10:1) and such system would protect the cores tablet of mesalamine up to 6 hr. and after that under the influence of pectinase the system would degrade faster and delivering 5-ASA to the colon.It was also evident from the results of drug release the presence and absence of pectinase enzyme that the maximum amount of drug release occurred by the degradation of the coat material by the enzymes. Stability studies of Fp3 batch for two month revealed that the formulations were stable up to 40±2 C and 75± 5% RH. It should be stored in a cool and dry place.The pectin-Chitosan envelope was found to be a promising drug delivery system for those drugs to be delivered to the colon. 
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